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Objective. Potential targets for treat-to-target
strategies in juvenile idiopathic arthritis are minimal dis-
ease activity (MDA) and clinically inactive disease (CID).
We undertook this study to compare short- and long-term
outcomes following achievement of MDA and CID on the
10-joint clinical Juvenile Arthritis Disease Activity Score
(cJADAS10) and following achievement of CID on
Wallace et al’s preliminary criteria.
Methods. Children recruited to the Childhood
Arthritis Prospective Study, a UK multicenter inception
cohort, were selected if they were recruited prior to Jan-
uary 2011 and diagnosed as having oligoarthritis or rheu-
matoid factor–negative or –positive polyarthritis. One year
following diagnosis, children were assessed for MDA on
the cJADAS10 and for CID on both Wallace et al’s prelimi-
nary criteria and the cJADAS10. Associations were tested
between those disease states and functional ability, absence
of joints with limited range of motion, psychosocial health,
and pain at 1 year and annually to 5 years.
Results. Of 832 children, 70% were female and the
majority had oligoarthritis (68%). At 1 year, 21% had
achieved CID according to both definitions, 7% according
to Wallace et al’s preliminary criteria alone, and 16%
according to the cJADAS10 alone; 56% had not achieved
CID. Only 10% of children in the entire cohort achieved
MDA without also achieving CID. Achieving either early
CID state was associated with a greater absence of joints
with limited range of motion. However, only CID according
to the cJADAS10 was associated with improved functional
ability and psychosocial health. Achieving CID was supe-
rior to achieving MDA in terms of short- and long-term
pain and the absence of joints with limited range of motion.
Conclusion. CID on the cJADAS10 may be prefer-
able as a treatment target to CID on Wallace et al’s pre-
liminary criteria in terms of both feasibility of application
and long-term outcomes.
Despite the licensing of biologic therapies for juve-
nile idiopathic arthritis (JIA) (1) and increasingly aggressive
treatment strategies (2), a recent systematic review estimatesThis report includes independent research funded by the
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that the burden of disease in JIA remains high, with fewer
than 50% of patients achieving remission after a decade of
disease (3). Following the success of treat-to-
target approaches in adult rheumatology (4,5), a similar
approach in JIA may yield better disease outcomes (6).
However, it is less clear what the target should be.One target
for children and young people with JIA is clinically inactive
disease (CID), a state in which no evidence of disease activity
is apparent (7). While a state of CID, and ultimately disease
remission, would be ideal, it may not be feasible in all chil-
dren due to the nature of their JIA disease activity. In addi-
tion, the treatment required for such a state may not be
acceptable when weighed against additional risks of adverse
events and the cost of additional therapies. An alternative
target could therefore be minimal disease activity (MDA), a
state that would include not only children with CID but also
those with low but persistent disease activity (8).
Defining disease states such as CID in clinical prac-
tice can be challenging and currently relies on composite
criteria (3,9). Multiple such definitions have been pro-
posed, including CID using Wallace et al’s preliminary cri-
teria (7), the American College of Rheumatology (ACR)
2011 CID criteria (10), and scoring below certain cutoffs
on the Juvenile Arthritis Disease Activity Score (JADAS)
(11) or clinical JADAS (cJADAS) (12). Wallace et al’s pre-
liminary criteria include 5 components, observed or mea-
sured by a physician, all of which must be absent or in the
normal range; these components do not include an assess-
ment by the patient or the patient’s proxy (7). In contrast,
the JADAS and cJADAS include fewer overall compo-
nents, meaning that they may be easier to complete in a
routine clinical setting. They do include the patient’s
assessment or a proxy’s subjective assessment of the
patient’s well-being (11,12). Although Wallace et al’s pre-
liminary criteria and low score cutoffs on the JADAS or
cJADAS are intended to identify similar disease con-
structs, a recent analysis has shown that these definitions
will classify different groups of children as having CID,
which may be driven by their different components (9). It
is currently unclear which definition, if any, should be
applied in the clinical setting as a treatment target, but the
choice may be influenced by how achievement of CID
according to each definition relates to later disease out-
comes. It is also unclear whether applying increasingly ag-
gressive treatment strategies to achieve CID beyond MDA
is favorable in terms of long-term outcomes.
Therefore, the aims of this study were 1) to
describe the impact of early achievement of CID on func-
tional ability, joint limitations, and psychosocial health
over the first 5 years following initial presentation to a
pediatric rheumatology clinic, 2) to assess whether the
applied definition of CID at 1 year is associated with
different long-term outcomes, and 3) to assess whether
achieving CID is beneficial beyond MDA in terms of pain
in addition to these outcomes according to the 10-joint
cJADAS (cJADAS10).
PATIENTS AND METHODS
Study population. This analysis included children
recruited to the Childhood Arthritis Prospective Study (CAPS), a
prospective inception cohort recruiting from 8 UK pediatric and
adolescent rheumatology centers since 2001. Details of this
cohort have been described previously (13). The CAPS was
approved by the Northwest Multicentre Research Ethics Com-
mittee, and written informed consent from guardians (and, where
appropriate, assent or consent from participants) was obtained.
For this study, children were included if they had a
physician’s diagnosis of JIA (oligoarticular and either rheuma-
toid factor [RF]–negative or –positive polyarticular categories)
and had been recruited to the CAPS prior to January 1, 2011
to allow for at least 5 years of follow-up. Children were
included in each analysis if outcome data were available for at
least one of the time points studied. Those who had not
returned study forms after initial presentation were excluded.
Data collection. CAPS data were collected from the med-
ical case notes at first presentation to a pediatric rheumatology
clinic (baseline date) and annually thereafter for 5 years using a
predefined study schedule. These include demographic and dis-
ease features, International League of Associations for Rheuma-
tology (ILAR) category (14) as recorded by the treating physician
in the case notes, and any antirheumatic treatments. Collection
of components of the CID/MDA criteria has been described
previously (9).
At each follow-up visit, proxies (or the children them-
selves where possible if they were age >11 years) were asked to
complete a series of patient-reported outcome measures, includ-
ing the Childhood Health Assessment Questionnaire (C-HAQ)
and the Child Health Questionnaire (CHQ) (15). The C-HAQ
score totals 24 and is divided so that final scores range from 0 to
3, with higher scores denoting poorer functional ability. It is
known to have a floor effect, whereby scores tend to cluster at
the “good functional ability” section of the scale (15). The CHQ
is a generic health-related quality of life (HRQoL) measure
designed for proxy completion for pediatric patients age >5
years. It comprises 15 subscales, 10 of which can be aggregated
to yield a psychosocial summary score. This summary score
ranges from 0 to 100, with higher scores denoting better HRQoL
(16). Scores below 30 are considered at least 2 standard devia-
tions below population averages (17). Patients/proxies also com-
pleted a 100-mm pain visual analog scale (VAS).
States of CID and MDA. Using data from 1 year follow-
ing initial presentation, children were categorized according to
their CID status on Wallace et al’s preliminary criteria (7) and
the cJADAS10 (12). Children were therefore classified as having
the following states: 1) CID on both criteria sets, 2) CID on
Wallace et al’s preliminary criteria only, 3) CID on the
cJADAS10 only, 4) no CID. Children were also classified as to
whether they fulfilled: 1) CID on the cJADAS10, 2) MDA but
not CID on the cJADAS10 (Table 1).
Outcome assessment. The following outcomes were
selected: functional ability on the C-HAQ, no joints with limited
range of motion, psychosocial health on the CHQ, and pain.
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These outcomes were selected to avoid circular reasoning. For
example, the cJADAS10 includes the proxy global assessment of
well-being and Wallace et al’s preliminary criteria do not. It
would therefore be expected that CID on the cJADAS10 would
be more strongly associated with better longitudinal proxy-
assessed well-being than would CID on Wallace et al’s prelimi-
nary criteria. To avoid this circular reasoning, all outcomes
selected for the current study must not have formed one of the
components of either CID/MDA criteria set. All outcomes were
assessed annually from baseline to 5 years following initial pre-
sentation to a pediatric rheumatology clinic.
Statistical analysis. First, associations were tested be-
tween 1-year CID/MDA states cross-sectionally with the out-
comes at 1 year. Second, associations between these 1-year
states and outcomes annually from 1 to 5 years following initial
presentation were analyzed via multilevel, multivariable regres-
sion analyses. All children with outcomes available for at least
one time point were included. Depending on the outcome, the
following regression analyses were applied: logistic (no joints
with limited range of motion versus any joints with limited
range of motion, CHQ psychosocial score <30 versus CHQ psy-
chosocial score ≥30) and linear (CHQ psychosocial score, pain)
regressions. The known floor effect of the C-HAQ, whereby
scores cluster at the “high functional ability” end of the scale
(15), prompted its analysis using zero-inflated negative binomial
regression models. These models incorporate the excessive zero
counts by first generating odds ratios (ORs) for having a score
of zero versus not. Second, they produce risk ratios for increas-
ing counts along the C-HAQ scale among those subjects who
have not scored zero. To analyze the C-HAQ in this way, each
value must be an integer. C-HAQ scores were therefore multi-
plied by 8 to yield their original score out of 24 points to allow
its analysis as a count variable. Because one component of the
cJADAS10 criteria set, the parental global assessment of well-
being, has been reported to be driven by pain (18–20), pain was
only used as an outcome when analyzing associations between
early CID and MDA on the cJADAS10.
Data were analyzed following multiple imputation under
assumptions detailed in previous work (9) for CID/MDA states
and under the assumption of data “missing at random” for out-
come data except CHQ psychosocial scores. Twenty imputed
data sets were generated using Stata software, version 14 (Stata-
Corp), and estimates from individual models were pooled using
Rubin’s Rules, where both within- and across-imputation vari-
ances are accounted for (21). CHQ psychosocial scores were not
imputed due to the likely unmeasured confounders that would
inform these data.
Random effects were included at the patient level for
longitudinal models. The zero-inflated longitudinal models
instead incorporated robust clusters at the patient level. Multi-
variable models were adjusted for hospital, age, symptom dura-
tion and year of presentation, sex, and ILAR category, and
models at 1 year were also adjusted for respective outcome at
baseline. Covariate multicollinearity was assessed via Spearman’s
correlations, and zero-inflated negative binomial models were
deemed preferable to Poisson models if dispersion parameter
95% confidence intervals (95% CIs) did not contain zero. All
analyses were completed using Stata software, version 14.
RESULTS
Patient cohort. A total of 1,106 patients had been
recruited to the CAPS by January 1, 2011. Of these, 274
were excluded (60 were diagnosed as having a non-JIA con-
dition, 209 did not have oligoarticular or polyarticular JIA,
and 5 had not returned study forms). This left 832 patients
for the current analyses, including 649 for whom we had
available data on the CHQ psychosocial score at any time
point (601 from 1 year onward). By the end of the 5-year
follow-up period, 510 children (61%) remained under care
of pediatric rheumatologists and had not been lost to fol-
low-up or discharged (see Supplementary Figure 1, avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.40519/abstract). The
numbers of children with available data for each outcome
across time points are shown in Supplementary Table 1,
http://onlinelibrary.wiley.com/doi/10.1002/art.40519/abstract.
Within the cohort, median age at initial presentation
to a pediatric rheumatology clinic was 6.9 years (inter-
quartile range [IQR] 3.1–11 years), and median symptom
duration at presentation was 5.5 months (IQR 2.9–11
months). Seventy percent of the cohort were females, and
68%, 28%, and 5% were diagnosed as having oligoarticular
JIA, RF-negative polyarticular JIA, and RF-positive
polyarticular JIA, respectively (Table 2).
Table 1. Definitions of CID and MDA applied to the Childhood Arthritis Prospective Study cohort*
Definition
Components
How to calculate
No. of joints
with active
disease
Physician’s
global
assessment
Parent’s
global
assessment ESR/CRP Uveitis
Systemic
features in
systemic JIA
CID according to Wallace et al’s
preliminary criteria (7)
Yes Yes No Yes Yes Yes Zero or normal across all
components
CID according to cJADAS10 (12) Yes Yes Yes No No No Total score ≤1
MDA according to cJADAS10 (12) Yes Yes Yes No No No For oligoarticular course,
score ≤1.5; for
polyarticular course,
score ≤2.5
* CID = clinically inactive disease; MDA = minimal disease activity; ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; JIA = juve-
nile idiopathic arthritis; cJADAS10 = 10-joint clinical Juvenile Arthritis Disease Activity Score.
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Frequency of CID and MDA among patients at 1
year.One year following initial presentation, the majority
of patients had not achieved CID (56%). Twenty-one
percent had achieved both CID states, and an additional
23% had achieved only one state of CID (16% on the
cJADAS10 and 7% on Wallace et al’s preliminary cri-
teria). On the cJADAS10, 48% of patients had achieved
MDA. Of those patients, 79% had also achieved CID
(38% of the entire cohort).
Association between early achievement of CID and
outcomes measured at 1 year. All estimates from complete
case analyses were similar to those following multiple
imputation (see Supplementary Tables 2 and 3, http://
onlinelibrary.wiley.com/doi/10.1002/art.40519/abstract). The
following results relate to imputed data, except for CHQ
psychosocial scores. All models met the tested assumptions.
At 1 year, achievement of any state of CID was
associated with significantly increased odds of having no
joints with limited range of motion (for Wallace et al’s
preliminary criteria only, OR 7.5 [95% CI 2.9, 19.2]; for
cJADAS10 only, OR 3.9 [95% CI 2.5, 6.3]; for both cri-
teria sets, OR 9.3 [95% CI 4.9, 17.7]). However, children
who had achieved CID only on Wallace et al’s preliminary
criteria but not on the cJADAS10 had no better CHQ
psychosocial scores or C-HAQ scores than those with
active disease at 1 year. In contrast, those children who
had achieved CID on at least the cJADAS10 scored at
least 5 points better on CHQ psychosocial health (for
cJADAS10 only, coefficient 5.3 [95% CI 0.5, 10.1]; for
both cJADAS10 and Wallace et al’s preliminary criteria,
coefficient 5.5 [95% CI 1.5, 9.4]) than did children with
active disease. Those children also had at least 4 times the
odds of having no disability recorded using the C-HAQ
(for cJADAS10 only, OR 4.5 [95% CI 2.2, 9.5]; for both
cJADAS10 and Wallace et al’s preliminary criteria, OR
5.2 [95% CI 2.7, 9.9]) than did those with active disease.
When assessing nonzero C-HAQ scores, children who
had achieved CID on the cJADAS10 had 50% lower
scores (for cJADAS10 only, 95% CI 20%, 60%; for both
cJADAS10 and Wallace et al’s preliminary criteria, 95%
CI 30%, 70%) (Table 3). Too few children who had
achieved CID on either criteria set scored <30 on CHQ
psychosocial health, so associations with this outcome
could not be tested.
Association between early MDA versus CID on the
cJADAS10 and outcomes measured at 1 year. Compared
with children who met the threshold for MDA on the
cJADAS10 but who did not also achieve CID, those who
did achieve CID had greater odds of no joints with limited
range of motion (OR 2.4 [95% CI 1.3, 4.5]) and lower
Table 2. Baseline characteristics of the patients in the Childhood Arthritis Prospective Study cohort*
Patients with available
baseline data, no. (%)
Median (IQR)
or no. (%)
Patients with available
data at 1 year, no. (%)
Median (IQR)
or no. (%)
Patient characteristics
Female 832 (100) 586 (70) – –
White or Caucasian 832 (100) 752 (90) – –
Age at onset, years 827 (99) 5.9 (2.4–9.9) – –
Age at first presentation, years 832 (100) 6.9 (3.1–11) – –
Symptom duration at diagnosis, months 827 (99) 5.5 (2.9–11) – –
ILAR category 832 (100) – –
Oligoarticular 563 (68) – –
RF polyarticular 231 (28) – –
RF+ polyarticular 38 (5) – –
Disease characteristics
No. of joints with active disease
(78 joints assessed)
784 (94) 2 (1–5) 689 (83) 0 (0–1)
No. of joints with limited range of
motion (78 joints assessed)
784 (94) 1 (1–3) 677 (81) 0 (0–1)
No joints with limited range of motion 784 (94) 161 (21) 677 (81) 391 (58)
PGA, 0–10-cm VAS 630 (76) 2.8 (1.5–5.0) 576 (69) 0.4 (0.0–1.8)
PGE, 0–10-cm VAS 546 (66) 2.1 (0.5–5.0) 587 (71) 0.6 (0.0–2.5)
ESR, mm/hour 517 (62) 16 (6–40) 194 (23) 8 (4–17)
CRP, mg/liter 474 (57) 7 (4–19) 173 (21) 4 (3–7)
Uveitis 644 (77) 27 (4.2) 673 (81) 30 (4.5)
C-HAQ score, 0–3 557 (67) 0.8 (0.1–1.4) 573 (69) 0.3 (0–0.9)
Pain, 0–100-mm VAS 552 (66) 30 (8–58) 572 (69) 8 (1–33)
CHQ score, 0–100 281 (34) 50 (39–55) 343 (41) 52 (43–58)
CHQ score ≤30 281 (34) 32 (11) 343 (41) 23 (6.7)
* IQR = interquartile range; ILAR = International League of Associations for Rheumatology; RF = rheumatoid factor; PGA = physician’s global
assessment of disease activity; VAS = visual analog scale; PGE = proxy’s global assessment of well-being; ESR = erythrocyte sedimentation rate;
CRP = C-reactive protein; C-HAQ = Childhood Health Assessment Questionnaire; CHQ = Child Health Questionnaire.
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VAS pain scores (coefficient 6.5 mm [95% CI 12.1
mm, 0.9 mm]) at 1 year. However, there were no signifi-
cant differences between these 2 groups of children in any
of the C-HAQ or CHQ psychosocial outcomes (Table 3).
Associations between disease activity state at 1
year and long-term outcomes. Early achievement of CID
on either criteria set was associated with between 2.0
times (for cJADAS10 only, 95% CI 1.5, 2.9) and 3.0 times
(for Wallace et al’s preliminary criteria only, 95% CI 1.4,
4.5; for both criteria sets, 95% CI 2.0, 4.5) the odds of no
joints with limited range of motion for each additional
year through 5 years compared with children who had
active disease at 1 year (Table 4). Achievement of CID on
the cJADAS10 was associated with better CHQ psychoso-
cial scores (for cJADAS10 only, b = 4.1 [95% CI 1.8, 6.4];
for both criteria sets, b = 3.9 [95% CI 1.6, 6.2]) and a
higher probability of both no disability and lower disability
among those with nonzero C-HAQ scores compared with
those with active disease. There was no difference in long-
term C-HAQ or CHQ scores between children who had
active disease at 1 year and those with CID according to
Wallace et al’s preliminary criteria but not according to
the cJADAS10 (Figure 1). There was no difference across
all groups in the proportion of children with CHQ scores
<30 (Table 4).
Associations between early MDA versus CID and
long-term outcomes. Compared with children who had
achieved MDA but not CID on the cJADAS10, those
who had achieved CID at 1 year had, on average with
each increasing year, 1.7 times the odds of no joints with
limited range of motion (95% CI 1.0, 2.7) and 5.5 mm
better pain scores (95% CI 10.1 mm, 0.9 mm) through
5 years. There was no difference between these patient
groups in C-HAQ or CHQ scores (Table 4 and Figure 2).
Figure 1. Outcomes over 5 years following initial presentation to a pediatric rheumatology clinic, split according to clinically inactive disease
(CID) state at 1 year. A, Median Childhood Health Assessment Questionnaire (C-HAQ) scores. Median C-HAQ scores over the 5 years were the
same whether CID was measured according to both Wallace et al’s preliminary criteria and the 10-joint clinical Juvenile Arthritis Disease Activity
Score (cJADAS10) or according to the cJADAS10 alone. B, Percentages of subjects having no joints with limited range of motion. C, Median
Child Health Questionnaire (CHQ) psychosocial scores.
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DISCUSSION
The success of treat-to-target strategies in adult
rheumatology, such as aiming for a low Disease Activity
Score in 28 joints (4,5,22), has prompted the consideration
of similar strategies in pediatric practice (6,23–26). One
central barrier to implementing treat-to-target approaches
in JIA is the lack of a single “best” target. Although most
would agree that CID is the ultimate target, there are mul-
tiple ways in which this disease state can be assessed in the
clinical setting. Also important in selecting a “best” out-
come measure for clinical practice is understanding how it
relates to longer term outcomes. Two such definitions were
assessed in this analysis: CID according to Wallace et al’s
preliminary criteria or according to the cJADAS10. These
2 scores differ in their components. Determination of CID
according to Wallace et al’s preliminary criteria is limited
to assessments by a physician or laboratory measures of
inflammation. These criteria also include an assessment
of uveitis activity (7). The cJADAS10 captures a lack of
inflammation, as assessed by the physician (although with
fewer components), but it also includes an assessment by
the patient/parent (12). It does not include uveitis activity.
The results of this analysis show that children who
achieve CID at 1 year according to either measure have
lower counts of joints with limited range of motion both at
1 year and over the next 4 years of follow-up. However,
children who achieved CID according to Wallace et al’s
preliminary criteria but not according to the cJADAS10
were consistently found to have high levels of disability and
poorer psychosocial function. Previous analysis has shown
that this difference is driven by lower levels of patient well-
being, despite the absence of joints with active disease or
other inflammatory manifestations of disease (9).
Figure 2. Outcomes over 5 years following initial presentation to a pediatric rheumatology clinic, split according to clinically active disease, clini-
cally inactive disease (CID), and minimal disease activity (MDA) on the 10-joint clinical Juvenile Arthritis Disease Activity Score (cJADAS10). A,
Median Childhood Health Assessment Questionnaire (C-HAQ) scores. B, Percentages of subjects having no joints with limited range of motion.
C, Median Child Health Questionnaire (CHQ) psychosocial scores. D, Median pain scores.
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This study benefitted from a large sample of pa-
tients with JIA in all 3 ILAR categories assessed, all of
whom were treated within a single health care service. The
scale of the data collected meant that 5-year outcomes
could be assessed following early achievement of different
CID states. In addition, robust methods, including imputa-
tion methods under clinically plausible assumptions, were
implemented to deal with the inevitable missing data asso-
ciated with observational cohorts. In particular, a large
proportion of patients were lost to follow-up. Informative
dropout in the majority of cases informed the imputation
methods for CID/MDA states. In turn, this information
was used to impute missing outcome values. Thus, al-
though precision of model estimates is affected by missing
data, the point estimates should be relatively unbiased.
A challenge is in understanding how best to apply
these results in the clinical setting. As achievement of
CID according to the cJADAS10 was associated with out-
comes equivalent or superior to those for CID achieved
according to Wallace et al’s preliminary criteria, and since
the cJADAS10 is more feasible to complete in clinical
practice because it contains only 3 routinely collected
components (27), one could argue that this is likely to be
a superior treatment target for application in clinical prac-
tice. However, a number of limitations of both the out-
come measure and the analysis should be considered.
As the 2 scores differ in their components, one
could argue that they are not capturing the same con-
struct. Wallace et al’s preliminary criteria capture more
objective measures of inflammation, while the cJADAS10,
through inclusion of a measure of patient well-being, may
also capture other noninflammatory components of the
disease, such as chronic pain and fatigue not captured by
Wallace et al’s preliminary criteria. However, in addition
to a single score/cutoff, the value of the individual compo-
nents of the cJADAS10 would be required to guide indi-
vidual treatment decisions. Although it is well recognized
that functional ability, HRQoL, and pain do improve fol-
lowing treatment with both methotrexate and biologic
therapies (28–33), treating to a cJADAS10 target may also
require a multifactorial treatment strategy, potentially
including interventions such as physiotherapy and psycho-
logical services for children with chronic pain in the
absence of joints with active disease. Otherwise, there is
the risk of intensifying or changing immunosuppressive
therapy in the absence of inflammation. Equally impor-
tant, relying solely on Wallace et al’s preliminary criteria
may guide immunosuppressive therapy very well but may
ignore other symptoms relevant to the patient.
At the outset of this analysis, it was also unknown
whether achievement of CID is associated with better out-
comes than those for patients who achieve MDA but not
CID. The present study found that achieving CID on the
cJADAS10 is associated with fewer joints with limited
range of motion compared with achieving MDA. However,
achieving CID above MDA was not associated with greater
improvements in C-HAQ or CHQ scores, either between
baseline and 1 year or from 1 to 5 years. Therefore, MDA
on the cJADAS10 may be an appropriate target when dis-
ease activity parameters are low but patient well-being is
poor. The risk of adverse effects with treatment intensifica-
tion should be considered, particularly if the attainment of
CID is deemed unlikely (34) or patient well-being is high.
A limitation of this study was that, to avoid circular
reasoning, important disease activity variables such as
counts of joints with active disease could not be used as
outcomes. Since the variables differentially form the CID
states, any state including said variable would be intrinsi-
cally more likely to associate with the outcome. The out-
comes selected for the study did, however, comprise
multiple physician- and patient-important outcomes.
However, these conclusions can only relate to oligoarticu-
lar and polyarticular JIA. The CID definitions have only
been validated in these categories, and it is likely that
additional components will need to be added to these cri-
teria sets in order to fully capture low and inactive disease
in less common JIA categories. In addition, due to a lack
of data on morning stiffness, we were not able to compare
outcomes following the achievement of the 2011 ACR
CID criteria with the other CID states. Finally, although
it has been suggested that treat-to-target strategies will
result in better long-term outcomes, during the period of
data collection for this study there was no formal treat-to-
target strategy in place in the UK. Therefore, although
the findings support the notion that early achievement of
CID is associated with better outcomes, the data cannot
be used to show that active treatment toward these targets
currently results in better long-term outcomes. Further
work will need to assess long-term outcomes following the
implementation of these guidelines.
In conclusion, early achievement of CID according
to the cJADAS10 is associated with long-term outcomes
equivalent or superior to those associated with early
achievement of CID according to Wallace et al’s prelimi-
nary criteria. Differences in the components of these 2 def-
initions and the implications for clinical practice through
implementation of a single score suggest that the optimal
definition of CID for application in a clinical setting
remains unclear. Further work, ideally involving con-
sumers, clinicians, and researchers, is needed to best
define treatment targets and treatment strategies for use
in JIA. The results do, however, highlight the importance
of addressing all aspects of JIA and not just the underlying
inflammation, in terms of best outcomes for the child.
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Clinical Images: By one’s own hand
The patient, a 23-year-old man, presented with digital ischemia in both hands after having injected buprenorphine into his wrists.
The injected material was prepared by dissolving a tablet of buprenorphine in water and pulling the milky solution through cotton
into a syringe. In the absence of accessible superficial veins in his forearms or hands, the patient routinely relied on veins in his
volar wrists for vascular access. Shortly after the most recent injections in both wrists, the patient developed pain and fixed viola-
ceous discoloration of both hands, prompting him to seek urgent medical attention. Examination results were notable for digital
ischemia involving the right fourth and fifth fingers and the left third and fourth fingers, with a livedoid pattern of ischemia
involving the palmar aspect of the left wrist (A). Blood cultures were sterile, and echocardiography findings were normal.
Antiphospholipid antibodies and cryoglobulins were absent, and serologic studies for hepatitis were negative. Contrast arteriogra-
phy was performed at the request of the vascular surgeons to determine the potential for microvascular surgical intervention. This
showed abrupt occlusion of the digital arteries involving the right thumb, fourth finger, and fifth finger (B) consistent with an
embolic process. The fingers on the left hand showed several filling defects involving the radial and ulnar arterial distributions.
These ischemic changes were attributed to particulate matter emboli from inadvertent intraarterial injections. The patient was
treated conservatively with analgesics, nifedipine, application of local heat, and cessation of dextroamphetamine/amphetamine that
had been previously prescribed for attention deficit hyperactivity disorder. Perfusion slowly improved over the next 4 days.
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